Today: 1 December 2025
Subscribe
Browse Category

NYSE:NVO News 10 November 2025 - 28 November 2025

US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

US Stock Market Today, Nov. 24, 2025: Futures Rise on Fed Rate-Cut Hopes, Bitcoin Rebound and Novo Nordisk Shock Before the Opening Bell

As Wall Street wakes up on Monday, November 24, 2025, U.S. stock futures are pointing to a positive open for the Dow Jones, S&P 500 and Nasdaq, kicking off a holiday‑shortened Thanksgiving week. Gains are being driven by rising expectations
25 November 2025
 ·  ·  ·  ·  · 
Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Danish pharma giant Novo Nordisk is under intense pressure today after its high‑profile Alzheimer’s trials for semaglutide failed, sending the stock to multi‑year lows and capping a brutal year for NVO shareholders. Novo Nordisk stock today: how far has NVO
24 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk stock is back on traders’ screens today as a cluster of fresh headlines – from high‑stakes Alzheimer’s trials to aggressive Wegovy price cuts and new Danish GDP data – reshapes the narrative around the Ozempic maker. On Thursday,
20 November 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Published November 18, 2025 Summary: Novo Nordisk (NYSE: NVO) remains in the spotlight after rolling out a U.S. self‑pay price cut for Wegovy and Ozempic—plus a two‑month $199 introductory offer for new patients—while its controlling shareholder Novo Holdings exited its
18 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Published November 17, 2025 Novo Nordisk moved aggressively today to cut out‑of‑pocket costs for its blockbuster GLP‑1 drugs Wegovy and Ozempic, unveiling new self‑pay prices and limited‑time offers that it says will reach tens of thousands of U.S. pharmacies and
17 November 2025
 ·  ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

Published: November 12, 2025 Summary: WeightWatchers says it will sell Wegovy in a pill once launched WeightWatchers (WW) plans to carry Novo Nordisk’s oral Wegovy, pending U.S. approval, leaning into consumer preference for pills over injections and differentiating from rivals
12 November 2025
 ·  ·  ·  ·  · 
Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Metsera (MTSR) Sinks as Pfizer Seals Revised $10B Buyout; 8‑K Spells Out $65.60 Cash + Up to $20.65 CVR — Nov. 10, 2025

Shares of Metsera, Inc. (NASDAQ: MTSR) slumped on Monday after the obesity‑drug developer said it will proceed with a sweetened takeover by Pfizer that ends a high‑stakes bidding war with Novo Nordisk. Metsera accepted Pfizer’s revised offer late Friday; Novo
10 November 2025
 ·  ·  ·  ·  ·  ·  · 
1 2 3 … 5
Go toTop